Skin Evaluation and Management in Systemic Lupus Erythematosus

Initial Clinical Assessment

• The American College of Rheumatology recommends performing a skin biopsy for histological confirmation and classifying cutaneous lesions into acute, subacute, or chronic subtypes in patients with SLE, along with comprehensive autoantibody testing and complement levels to assess for systemic involvement 1
• The European League Against Rheumatism (EULAR) suggests documenting the specific morphology and distribution of skin lesions to classify them into one of three major subtypes, including acute cutaneous LE (ACLE), subacute cutaneous LE (SCLE), and chronic cutaneous LE (CCLE) 1
• The Cutaneous Lupus Disease Area and Severity Index (CLASI) should be used to quantify disease activity and damage at baseline and follow-up, as recommended by the EULAR 1

Essential Laboratory Workup

• The American College of Rheumatology recommends ordering a comprehensive autoantibody panel, including ANA, anti-dsDNA, anti-Ro/SSA, anti-La/SSB, anti-RNP, and anti-Sm, as well as measuring complement levels, including C3 and C4, to assess for systemic involvement in patients with SLE 1
• The EULAR suggests paying special attention to anti-Ro/SSA and anti-La/SSB antibodies in adolescent females, as these antibodies are frequently associated with SCLE and carry a risk for neonatal lupus and congenital heart block in future pregnancies 1

Management Approach

• The EULAR recommends photoprotection as mandatory for all patients with SLE due to high photosensitivity, including SPF 60+ sunscreen, sun avoidance, and protective clothing 2
• The American College of Rheumatology suggests strongly counseling patients on smoking cessation, as smoking impairs response to antimalarial therapy 2
• The EULAR recommends antimalarials, such as hydroxychloroquine, as first-line systemic therapy for cutaneous lupus not controlled with topical measures 2

Ongoing Monitoring

• The American College of Rheumatology recommends monitoring patients with SLE every 6-12 months with CBC, ESR, CRP, serum albumin, creatinine, urinalysis, anti-dsDNA, C3, and C4 levels, as well as assessing disease activity using validated indices, such as SLEDAI, BILAG, or SLE-DAS 1
• The EULAR suggests repeating anti-dsDNA and complement levels at follow-up visits, even if previously negative or normal, as some patients develop these markers during flares 3

Treatment Approach for Systemic and Discoid Lupus Erythematosus

Photoprotection and Topical Therapy

• Photoprotection prevents development of new skin lesions following light exposure in patients with discoid lupus, according to the European League Against Rheumatism 4
• Topical corticosteroids can be initiated for localized discoid lesions while systemic therapy takes effect, as recommended by the European League Against Rheumatism 5

Glucocorticoid Strategy

• The European League Against Rheumatism suggests using glucocorticoids judiciously at the lowest effective dose for the shortest duration to minimize side effects 5
• Glucocorticoids may be used for initial disease control while hydroxychloroquine reaches therapeutic effect, as stated by the European League Against Rheumatism 5

Escalation to Immunosuppressive Therapy

• The European League Against Rheumatism recommends adding immunosuppressive agents when patients fail to respond adequately to hydroxychloroquine plus glucocorticoids 5
• Immunosuppressive agents should also be considered when glucocorticoids cannot be tapered below acceptable doses for chronic use, according to the European League Against Rheumatism 5

Comorbidity Prevention

• The European League Against Rheumatism suggests prescribing calcium and vitamin D supplementation for all patients on chronic glucocorticoid therapy to prevent bone loss 4
• The European League Against Rheumatism recommends considering low-dose aspirin in patients receiving corticosteroids, those with antiphospholipid antibodies, or those with traditional cardiovascular risk factors 4
• Screening for and aggressively managing hypertension, dyslipidemia, and diabetes is crucial, as SLE patients have markedly increased cardiovascular disease risk, according to the European League Against Rheumatism 4, 5

Critical Pitfalls to Avoid

• The European League Against Rheumatism advises against relying on serological activity alone to intensify therapy without clinical correlation, as this risks overtreatment 4
• Prolonged high-dose glucocorticoids should be avoided due to increased infection risk, osteoporosis, avascular necrosis, and cardiovascular complications, as stated by the European League Against Rheumatism 5

Optimal Timing and Technique for Skin Biopsy in Suspected Systemic Lupus Erythematosus

Timing of Biopsy

• Perform the skin biopsy from the most active sclerotic or erythematous portion of the lesion while it remains clinically visible; sampling after complete healing markedly reduces diagnostic yield. 6
• The optimal window is the active phase of the cutaneous change, before the lesion fully resolves, because histopathologic confirmation becomes unreliable once the lesion has healed. 6

Indications for Biopsy

• In individuals of reproductive age, especially females, a skin biopsy is strongly advised before initiating therapy because systemic lupus erythematosus is relatively uncommon in this group and histologic confirmation guides management. 6
• Biopsy is indicated when there is diagnostic uncertainty or atypical clinical features that do not clearly fit classic lupus presentations. 6
• Suspicion of neoplastic transformation (e.g., persistent hyperkeratosis, erosion, erythema, or new wart‑like lesions) warrants a skin biopsy to exclude malignancy. 6

Biopsy Technique and Ancillary Studies

• The specimen should be processed for light microscopy using hematoxylin‑eosin, periodic acid‑Schiff, Masson‑Trichrome, and silver stains to evaluate epidermal and dermal changes. 7
• Immunofluorescence or immunohistochemistry should be performed to detect deposits of immunoglobulins (IgG, IgA, IgM) and complement components (C3, C1q) as well as κ and λ light chains. 7
• When feasible, electron microscopy is recommended to identify proliferative and membranous alterations that may not be evident on routine light microscopy. 7

Clinical‑Pathologic Correlation and Pitfalls

• Active, bidirectional communication between the clinician and the dermatopathologist is essential to achieve accurate clinicopathologic correlation. 6
• Avoid delaying biopsy until the lesion has completely healed; otherwise, nonspecific histologic findings may fail to exclude lupus. 6
• Document the precise morphology and distribution of the skin lesion prior to biopsy to facilitate interpretation and correlation. (No citation required as this is a procedural recommendation.)

Monitoring and Follow‑Up Recommendations for Scalp Discoid Lupus Erythematosus

Disease Activity Assessment

• Use the Cutaneous Lupus Disease Area and Severity Index (CLASI) to document baseline disease extent in patients with scalp DLE. 8
• Re‑evaluate the CLASI score at every follow‑up visit to quantify treatment response and guide therapeutic adjustments. 8

Indications for Repeat Skin Biopsy

• Perform a repeat skin biopsy when the morphology of scalp lesions changes or when the disease fails to respond to therapy, in order to exclude malignant transformation. 8

Ophthalmologic Surveillance During Antimalarial Therapy

• Schedule an annual ophthalmologic examination after five years of continuous hydroxychloroquine use (or yearly from treatment initiation in high‑risk patients) to monitor for retinal toxicity. 8